Rajender Aparasu to Adult
This is a "connection" page, showing publications Rajender Aparasu has written about Adult.
Connection Strength
2.040
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.150
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.149
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.149
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.148
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.143
-
Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
Score: 0.137
-
Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
Score: 0.137
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.135
-
Machine learning methods to predict 30-day hospital readmission outcome among US adults with pneumonia: analysis of the national readmission database. BMC Med Inform Decis Mak. 2022 11 09; 22(1):288.
Score: 0.130
-
Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
Score: 0.127
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.124
-
Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Med. 2021 10 08; 22(10):2224-2234.
Score: 0.120
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.116
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.110
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.110
-
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023 01; 359:114238.
Score: 0.032
-
Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
Score: 0.024